ISIN: INE858L01010PharmaceuticalsSmall Cap
CONCORD Concord Drugs Limited
68.87-0.92(-1.32%)
BSE20-Nov-202604:01:17 PM
Day’s Open
68.00
Prev Day Close
69.79
Market Cap (in Cr)
91.95
ATP
68.32
Volume
1,229
Avg. 3month Vol
4,636
Lower Circuit Limit
54.81
Upper Circuit Limit
82.21
20 Nov 2026 04:01:17 PM
Concord Drugs Share - Key Metrics
19-Nov-2026, 6:30 PM
| Market Cap(₹ Cr) | 91 |
| Face Value | 10.00 |
| Beta 1Yr | 0.49 |
| Shares OS (in cr) | 1.32 |
| Earnings Per Share (TTM) | 2.31 |
| Book Value Per Share (TTM) | 38.50 |
| Dividend | 0.00 |
Concord Drugs Share Price - Historic Returns
20-Nov-2026, 10:31 AM
| 1 Week | -3.92% | NA | NA |
| 1 Month | +3.15% | NA | NA |
| 3 Month | -3.01% | NA | NA |
| 6 Month | -14.71% | NA | NA |
| 1 Year | -15.34% | -11.14% | -4.20% |
| 3 Year | +103.76% | +17.80% | 85.96% |
| 5 Year | +136.67% | +67.56% | 69.11% |
| YTD | -16.50% | -9.12% | -7.38% |
Concord Drugs Share - Growth Metrics
| Sales | 114.17% | 14.77% |
| EBITDA | 57.14% | -0.44% |
| PAT | 434.55% | 1.98% |
| EPS | 298.28% | -8.95% |
| Sales | 122.78% | 13.92% |
| EBITDA | 66.35% | -0.78% |
| PAT | 490.00% | 5.39% |
| EPS | 332.08% | -6.29% |
*TTM: ending
SEP '26
*Annual: ending
MAR '26
Concord Drugs Ltd. Share - Volume Analysis
20-Nov-2026, 6:25 PM
Today
1.23K
Yesterday
6.75K
5.94K
88 %
5 Day Avg
4.28K
3.70K
86.37 %
30 Day Avg
3.87K
3.07K
79.25 %
Total VolDelivery Volume
Concord Drugs Share - Valuation Summary
| PE Ratio | 32.07 | 87.79 |
| P/Bv | 1.87 | 1.98 |
| EV/EBITDA | 16.27 | 23.34 |
| EV/Sales | 1.21 | 1.35 |
| MCAP/Sales | 0.98 | 1.18 |
| PE Ratio | 32.07 | 87.79 |
| P/Bv | 1.87 | 1.98 |
| EV/EBITDA | 16.27 | 23.34 |
| EV/Sales | 1.21 | 1.35 |
| MCAP/Sales | 0.98 | 1.18 |
*TTM ending
SEP '26
*Annual: ending
MAR '26
Concord Drugs Share - Seasonality Returns Analysis
Stock Scan
| Period | Jan | Feb | Mar | Apr | May | Jun | July | Aug | Sept | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monthly Avg | ||||||||||||
| 2019 |
< -10
-10 to -5
-5 to 0
0 to 5
5 to 10
> 10
Concord Drugs Share Price - Technical Summary
19-Nov-2026
Pivot Level
R171.97 | Pivot 69.81 | S167.63 |
R274.15 | S265.47 | |
R376.31 | S363.29 |
Technical Moving Average
0
8
Bullish
Bearish
| 5 | 70.90 | 1.59% abv LTP |
| 10 | 70.70 | 1.30% abv LTP |
| 12 | 70.60 | 1.16% abv LTP |
| 20 | 70.40 | 0.87% abv LTP |
| 26 | 70.50 | 1.02% abv LTP |
| 50 | 71.60 | 2.59% abv LTP |
| 100 | 73.20 | 4.89% abv LTP |
| 200 | 73.00 | 4.60% abv LTP |
| 5 | 71.00 | 1.73% abv LTP |
| 10 | 71.50 | 2.45% abv LTP |
| 20 | 68.90 | 1.28% blw LTP |
| 30 | 69.20 | 0.85% blw LTP |
| 50 | 72.40 | 3.74% abv LTP |
| 100 | 73.20 | 4.89% abv LTP |
| 150 | 75.80 | 8.61% abv LTP |
| 200 | 76.00 | 8.90% abv LTP |
Technical Indicators
4
3
Bullish
Bearish
Relative Strength Index47.93
RSI is mid-range
Money Flow Index39.07
MFI is mid-range
MACD0.08
MACD above Signal and Center
MACD Signal-0.31
MACD above Signal and Center
Average True Range4.21
Average Directional Index21.73
Rate of Change (21)4.52
Rate of Change (125)-12.76
Day Commodity Channel Index11.20
William-53.00
-53.04 William
Stochastic Oscillator61.72
Stochastic Oscillator %D67.76
Stochastic RSI67.07
Stochastic RSI %D74.56
Awesome Oscillator1.01
Ultimate Oscillator35.97
Momentum Oscillator-1.74
Concord Drugs Ltd. Share Price - Key Fundamentals
Financial Analysis
FY End Trend | MAR '26 | MAR '25 | MAR '24 | MAR '23 | MAR '22 |
Net Sales Growth % | 78.74 +74.05% | 45.24 +0.71% | 44.92 -13.75% | 52.08 -11.67% | 58.96 NA |
Total Expenditure Growth % % of Sales | 74.22 +80.54% +94.26% | 41.11 +0.51% +90.87% | 40.90 -13.89% +91.05% | 47.50 -11.02% +91.21% | 53.38 NA +90.54% |
Growth % Margin % | 4.52 +9.44% +5.74% | 4.13 +2.74% +9.13% | 4.02 -12.23% +8.95% | 4.58 -17.92% +8.79% | 5.58 NA +9.46% |
Depreciation | 1.37 | 1.43 | 1.56 | 1.63 | 1.76 |
EBIT Growth % Margin % | 3.15 +16.67% +4.00% | 2.70 +9.76% +5.97% | 2.46 -16.61% +5.48% | 2.95 -22.77% +5.66% | 3.82 NA +6.48% |
Interest % of EBIT | 1.71 +54.29% | 2.03 +75.19% | 1.87 +76.02% | 1.71 +57.97% | 1.68 +43.98% |
Other income | 0.03 | 0.01 | 0.01 | 0.01 | 0.10 |
Minority int (before tax) | - | - | - | - | - |
Profit Before Tax Growth % Margin % | 1.47 +116.18% +1.87% | 0.68 +13.33% +1.50% | 0.60 -52.00% +1.34% | 1.25 -44.20% +2.40% | 2.24 NA +3.80% |
Total Tax Tax Rate % | 0.42 +28.57% | 0.35 +51.47% | 0.16 +26.67% | 0.26 +20.80% | 0.65 +29.02% |
Profit After Tax Growth % Margin % | 1.05 +218.18% +1.33% | 0.33 -25.00% +0.73% | 0.44 -55.56% +0.98% | 0.99 -37.74% +1.90% | 1.59 NA +2.70% |
Minority int (after tax) | - | - | - | - | - |
Profit/Loss of Associate Company | - | - | - | - | - |
PAT after Minority int & P/L Asso.Co. | 1.05 | 0.33 | 0.44 | 0.99 | 1.59 |
Extraordinary Items | - | - | - | - | - |
Adj Profit After Tax Growth % Margin % | 1.05 +218.18% +1.33% | 0.33 -25.00% +0.73% | 0.44 -55.56% +0.98% | 0.99 -37.74% +1.90% | 1.59 NA +2.70% |
EPS (Adj) | 0.80 | 0.34 | 0.47 | 1.06 | 1.82 |
Dividend Per Share Adj.(Rs) | - | - | - | - | - |
Book Value (Adj) (Unit Curr.) | 35.43 | 34.11 | 33.82 | 33.43 | 32.44 |
FY End Trend | MAR '26 | MAR '25 | MAR '24 | MAR '23 | MAR '22 |
Liabilities | |||||
Total Shareholders Funds | 48.52 | 34.11 | 33.82 | 31.70 | 28.36 |
Minority int | - | - | - | - | - |
Total Debt | 14.51 | 19.24 | 17.52 | 16.96 | 16.43 |
Policy Holders Fund | - | - | - | - | - |
Other Liabilities | 2.87 | 2.91 | 2.86 | 2.47 | 2.09 |
Total Liabilities | 65.90 | 56.26 | 54.20 | 51.13 | 46.88 |
Assets | |||||
Net Block | 11.58 | 12.21 | 11.67 | 12.92 | 13.97 |
Lease Adjustment | - | - | - | - | - |
Capital Work in Progress | 2.43 | 2.00 | 1.63 | 0.92 | 0.55 |
Investments | 0.78 | 0.80 | 0.84 | 0.89 | - |
Loans | - | - | - | - | - |
Inventories | 25.52 | 25.27 | 22.92 | 20.06 | 17.49 |
Sundry Debtors | 24.38 | 13.60 | 12.73 | 15.81 | 22.86 |
Cash and Bank | 0.75 | 0.23 | 0.18 | 0.10 | 0.07 |
Loans and Advances | 2.67 | 1.66 | 1.69 | 7.48 | 1.48 |
Total Current Assets | 53.32 | 40.76 | 37.52 | 43.45 | 41.90 |
Less : Current Liabilities and Provisions | |||||
Current Liabilities | 7.95 | 8.05 | 3.91 | 6.18 | 8.24 |
Provisions | 0.41 | 0.21 | 0.22 | 0.38 | 0.67 |
Total Current Liabilities | 8.36 | 8.26 | 4.13 | 6.56 | 8.91 |
Net Current Assets | 44.96 | 32.50 | 33.39 | 36.89 | 32.99 |
Miscellaneous Exp. not written off | - | - | - | - | - |
Deferred Tax Assets | - | - | - | - | - |
Deferred Tax Liability | 0.63 | 0.63 | 0.47 | 0.54 | 0.66 |
Net Deferred Tax | -0.63 | -0.63 | -0.47 | -0.54 | -0.66 |
Other Assets | 6.78 | 9.38 | 7.14 | 0.05 | 0.03 |
Total Assets | 65.90 | 56.26 | 54.20 | 51.13 | 46.88 |
FY End Trend | MAR '26 | MAR '25 | MAR '24 | MAR '23 | MAR '22 |
Cash and Cash Equivalents at Beginning of the year | - | - | - | - | - |
Net Cash from Operating Activities | -6 | 4 | 1 | 2 | 1 |
Net Cash Used in Investing Activities | -1 | -2 | -1 | -2 | -2 |
Net Cash Used in Financing Activities | 7 | -1 | - | 1 | 2 |
Net inc/(Dec) in Cash and Cash Equivalent | - | - | - | - | - |
Cash and Cash Equivalents at End of the year | - | - | - | - | - |
Other Bank Balance | - | - | - | - | - |
Total Cash & Bank | 1 | - | - | - | - |
FY End Sales Growth EBITDA Growth EBIT Growth Profit Before Tax Growth Profit After Tax Growth Adj Profit After Tax Growth Sales 3 yr CAGR EBITDA 3 yr CAGR Adj Profit After Tax 3 yr CAGR | MAR '26 +74.05% +9.44% +16.67% +116.18% +218.18% +218.18% +14.77% -0.44% +1.98% | MAR '25 +0.71% +2.74% +9.76% +13.33% -25.00% -25.00% -8.45% -9.54% -40.79% | MAR '24 -13.75% -12.23% -16.61% -52.00% -55.56% -55.56% - - - | MAR '23 -11.67% -17.92% -22.77% -44.20% -37.74% -37.74% - - - | MAR '22 NA NA NA NA NA NA - - - |
FY End EBITDA EBIT Profit Before Tax Profit After Tax Adj Profit After Tax | MAR '26 +5.74% +4.00% +1.87% +1.33% +1.33% | MAR '25 +9.13% +5.97% +1.50% +0.73% +0.73% | MAR '24 +8.95% +5.48% +1.34% +0.98% +0.98% | MAR '23 +8.79% +5.66% +2.40% +1.90% +1.90% | MAR '22 +9.46% +6.48% +3.80% +2.70% +2.70% |
FY End Debt Equity Ratio Long Term Debt Equity Ratio Interest Coverage Ratio | MAR '26 0.41 0.05 +54.29% | MAR '25 0.54 0.04 +75.19% | MAR '24 0.53 0.04 +76.02% | MAR '23 0.56 0.06 +57.97% | MAR '22 0.58 0.06 +43.98% |
FY End Return on Capital Employed Return on Networth | MAR '26 +5.22% +2.57% | MAR '25 +4.94% +1.00% | MAR '24 +4.75% +1.43% | MAR '23 +6.04% +3.30% | MAR '22 +8.36% +5.61% |
FY End Fixed Asset Turnover Inventory Turnover Debtors Turnover | MAR '26 1.95 3.10 4.15 | MAR '25 1.16 1.88 3.44 | MAR '24 1.19 2.09 3.15 | MAR '23 1.39 2.77 2.69 | MAR '22 1.59 3.37 2.58 |
FY END Price to Earnings (PE) Price to Book Value (PBV) EV to EBITDA EV to Sales | TTM 32.07 1.87 16.27 1.21 | 2026 87.79 1.98 23.34 1.35 | 2025 91.41 0.91 12.08 1.11 | 2024 74.83 1.04 12.96 1.17 | 2023 25.90 0.82 9.26 0.78 |
FY End EPS DPS Book Value Face Value | MAR '26 0.80 - 35.43 10.00 | MAR '25 0.34 - 34.11 10.00 | MAR '24 0.47 - 33.82 10.00 | MAR '23 1.06 - 33.43 10.00 | MAR '22 1.82 - 32.44 10.00 |
Concord Drugs Share - SWOT Analysis
- Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
- Companies with high TTM EPS Growth
- Growth Stars: Strongest Annual EPS Performers
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Companies with Low Debt
- Book Value per share Improving for last 2 years
- Companies with Zero Promoter Pledge
- Declining Revenue every quarter for the past 2 quarters
- Weak Momentum: Price below Short, Medium and Long Term Averages
- Increasing Trend in Non-Core Income
Data not available
Data not available
Concord Drugs Ltd. Share - Corporate Actions/News
Live News
No Data available
Concord Drugs Share - Deals Summary
| Reported on | Client Name/Category | Mode | Average Price | Action | No of shares (% of total) |
|---|---|---|---|---|---|
| 02-Dec-25 | S Koni Reddy | NA | 5,00,000 (3.80%) | ||
| 02-Dec-25 | S Nagi Reddy | NA | 5,00,000 (3.80%) | ||
| 02-Dec-25 | S Manoj Kumar Reddy | NA | 5,00,000 (3.80%) | ||
| 24-Nov-25 | S Koni Reddy | 9.07 | 5,50,000 (4.17%) | ||
| 24-Nov-25 | S Manoj Kumar reddy | 36.30 | 1,50,000 (1.14%) | ||
| 24-Nov-25 | S Nagi Reddy | 36.30 | 2,00,000 (1.52%) |
| Reported on | Client Name/Category | Average Price | Action | No of shares (% of total) |
|---|---|---|---|---|
| 04-Jul-25 | PRADEEP KUMAR JAIN | 54.48 | 69,944 (0.53%) | |
| 03-Jul-25 | GANGA DEVI LOYA | 53.25 | 51,655 (0.39%) | |
| 03-Jul-25 | PRADEEP KUMAR JAIN | 53.21 | 1,49,164 (1.13%) | |
| 03-Jul-25 | GANGA DEVI LOYA | 53.90 | 11,555 (0.09%) | |
| 30-Jun-25 | GANGA DEVI LOYA | 38.66 | 51,571 (0.39%) | |
| 15-Jan-24 | LAKSHMI PRASANNA PALLETI | 44.63 | 51,994 (0.39%) |
About Company
About Concord Drugs Limited
Key Brands
- Concord Drugs
Industry
Pharm-Ind-BD&For
Contact Information
Tel. No.
91-40-24036379
Fax No.
null
Company website
http://www.concorddrugs.in
Details
BSE
CONCORD
NSE
CONCORD
Series
EQ
ISIN
INE858L01010
Executive Summary
Chairman / Executive Director / M D / Promoter
S Nagi Reddy
ED / WTD / CFO / Promoter
Koni Reddy
WTD & Executive Director
S. Manoj Kumar Reddy
Independent Non Exe. Director
K Ramchandra Reddy
Independent Non Exe. Director
Summela Kasu
Understanding Sections
Insider Trading and SAST
Back to Insider Trading and SAST
Insider trading refers to trading in a shares by someone who has access to non-public, material information about that stock that can affect the stock’s price. SAST (Substantial Acquisition of Shares and Takeovers) refers to trades which involve high volume resulting in the acquirer acquiring substantial number of shares and voting rights in the target company (Substantial Acquisition of Shares) or taking over the control of the target company (Takeovers)
Seasonality Analysis
Back to Seasonality Analysis
Seasonality Analysis shows how a stock / index performs during a month across years based on various parameters like average returns, number of positive years, number of negative years etc. For indices you can also check the stocks which perform better/worse during a month across the years.